Non-Alcoholic Fatty Liver Disease and Metabolic Syndrome in Women: Effects of Lifestyle Modifications.
NAFLD
diet
elastosonography
lifestyle modifications
metabolic syndrome
obesity
ultrasound
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
13 May 2022
13 May 2022
Historique:
received:
14
04
2022
revised:
11
05
2022
accepted:
11
05
2022
entrez:
28
5
2022
pubmed:
29
5
2022
medline:
29
5
2022
Statut:
epublish
Résumé
Non-alcoholic fatty liver disease (NAFLD) is the most widespread liver disease, characterized by fatty acids liver accumulation and subsequent fibrosis. NAFLD prevalence ranges from 80% to 90% in obese subjects and is estimated to be around 50% in patients with metabolic syndrome. In this clinical scenario, diet and lifestyle modifications can play an important role. There are several imaging techniques that can accurately diagnose fatty liver. Recently, ultrasound has acquired a leading role in the diagnosis and follow-up of fatty liver disease. Furthermore, elastosonography represents a valid alternative to liver biopsy. Shear wave elastosonography evaluates the elastic and mechanical properties of liver tissue. The aim is to evaluate the effects of lifestyle and nutritional interventions and a loss of body weight during hepatic steatosis through ultrasonographic and elastosonographic techniques. Thirty-two female subjects with metabolic syndrome were subjected to clinical, anthropometric, and laboratory assessments, as well as abdominal ultrasonographic/elastosonographic measurements taken from enrollment time (T0) and after 3 months (T1) of lifestyle modifications. After 3 months of lifestyle changes, significant weight loss was observed, with a marked improvement in all adiposity indices. The laboratory parameters at T1 showed significant decreases in total and LDL cholesterol, triglycerides, basal blood glucose, 120 min glycaemia, basal insulin and HOMA Index (p < 0.001). A similar improvement was observed at T1 for steatosis degree (p < 0.01) and elastosonographic measurements (Kpa p < 0.001). The linear regression analysis of the baseline conditions documented that the size of the liver positively correlated with body weight, BMI, neck and waist circumferences, waist to height ratio (WhtR), insulin and HOMA Index, fat mass and visceral fat, and steatosis grade. After 3 months, the liver size showed improvement with positive correlations to all previous variables. Hepatic stiffness (Kpa) positively correlated with neck circumference, visceral fat, and ALT, with basal insulin, gamma-GT, and AST, and with waist circumference, WhtR, and fat mass. The degree of steatosis was positively correlated with more variables and with greater statistical significance at T1 with respect to T0. Particularly, the positive correlations between the degree of steatosis and neck circumference (p < 0.001), HOMA Index, and triglycerides (p < 0.001) appeared to be very significant. NAFLD management in women with metabolic syndrome should be focused on lifestyle modifications. Moreover, liver involvement and improvement at follow-up could be evaluated in a non-invasive manner through ultrasonographic and elastosonographic techniques.
Identifiants
pubmed: 35628889
pii: jcm11102759
doi: 10.3390/jcm11102759
pmc: PMC9146022
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Lancet. 2010 Jan 16;375(9710):181-3
pubmed: 20109902
PLoS One. 2017 Jun 1;12(6):e0178473
pubmed: 28570615
J Hepatol. 2012 Jan;56(1):255-66
pubmed: 21723839
World J Hepatol. 2015 Jun 8;7(10):1325-36
pubmed: 26052378
Arterioscler Thromb Vasc Biol. 2008 Jun;28(6):1039-49
pubmed: 18356555
JAMA Intern Med. 2019 Sep 01;179(9):1262-1271
pubmed: 31260026
Diabetes Care. 2013 Jan;36 Suppl 1:S11-66
pubmed: 23264422
J Clin Transl Endocrinol. 2014 Jul 23;1(4):133-139
pubmed: 29159094
Br J Nutr. 2004 Aug;92(2):311-9
pubmed: 15333163
Ultraschall Med. 2017 Aug;38(4):e48
pubmed: 30176678
J Ultrasound. 2020 Sep;23(3):265-278
pubmed: 32125676
Hepatology. 2007 Nov;46(5):1387-91
pubmed: 17685472
Eur J Endocrinol. 2012 Mar;166(3):503-10
pubmed: 22170794
Aliment Pharmacol Ther. 2011 Mar;33(5):525-40
pubmed: 21198708
Semin Liver Dis. 2008 Nov;28(4):339-50
pubmed: 18956290
Clin Nutr. 2009 Feb;28(1):46-51
pubmed: 19010573
Endocr Res. 2017 Feb;42(1):6-14
pubmed: 27050332
Nutrients. 2019 Dec 03;11(12):
pubmed: 31817038
Hepatology. 2016 Jul;64(1):73-84
pubmed: 26707365
Intern Med. 2009;48(10):739-46
pubmed: 19443967
Nutr Metab Cardiovasc Dis. 2012 Feb;22(2):120-6
pubmed: 20880682
Am J Gastroenterol. 2017 Dec;112(12):1832-1839
pubmed: 29063908
Diabetologia. 2012 Apr;55(4):885-904
pubmed: 22278337
Lancet. 2005 Sep 24-30;366(9491):1059-62
pubmed: 16182882
J Am Coll Cardiol. 2019 Mar 5;73(8):948-963
pubmed: 30819364
Nat Rev Gastroenterol Hepatol. 2018 Jan;15(1):11-20
pubmed: 28930295
Obes Rev. 2012 Jan;13(1):27-42
pubmed: 21917110
Can J Gastroenterol Hepatol. 2018 Jul 2;2018:2784537
pubmed: 30065915
Clin Imaging. 2009 Mar-Apr;33(2):110-5
pubmed: 19237053
Turk J Gastroenterol. 2019 Feb;30(2):163-170
pubmed: 30541716
Am J Gastroenterol. 2009 Apr;104(4):861-7
pubmed: 19293782
Antioxid Redox Signal. 2011 Sep 1;15(5):1325-65
pubmed: 20969475
J Acad Nutr Diet. 2012 Mar;112(3):401-9
pubmed: 22717200
Sci Rep. 2018 Mar 19;8(1):4788
pubmed: 29555959
J Hepatol. 2015 Apr;62(1 Suppl):S47-64
pubmed: 25920090
Clin Chem. 1972 Jun;18(6):499-502
pubmed: 4337382
Antioxidants (Basel). 2021 Feb 10;10(2):
pubmed: 33578702
Diabetes Metab Syndr. 2017 Oct - Dec;11(4):257-263
pubmed: 27578617
Am J Epidemiol. 2013 Jul 1;178(1):38-45
pubmed: 23703888
Annu Rev Pathol. 2007;2:31-56
pubmed: 18039092
Am J Clin Nutr. 1996 Sep;64(3 Suppl):524S-532S
pubmed: 8780375
Dig Liver Dis. 2015 Mar;47(3):181-90
pubmed: 25739820
Int J Obes Relat Metab Disord. 2002 Jun;26(6):873-5
pubmed: 12037660
Clin Sci (Lond). 2013 Oct;125(8):391-400
pubmed: 23627434
World J Hepatol. 2017 Apr 18;9(11):533-543
pubmed: 28469809
Aliment Pharmacol Ther. 2012 Oct;36(8):772-81
pubmed: 22958053
J Hepatol. 2017 Oct;67(4):829-846
pubmed: 28545937
Diabetes Obes Metab. 2020 Dec;22(12):2408-2416
pubmed: 32761721
Obes Res. 2003 Feb;11(2):226-31
pubmed: 12582218
J Lifestyle Med. 2015 Mar;5(1):7-13
pubmed: 26528424
PLoS One. 2015 Sep 29;10(9):e0139310
pubmed: 26418083
Liver Int. 2017 Jan;37 Suppl 1:81-84
pubmed: 28052624
Am J Kidney Dis. 2014 Oct;64(4):638-52
pubmed: 25085644
Hepatology. 2003 Apr;37(4):917-23
pubmed: 12668987
J Gastroenterol Hepatol. 2016 May;31(5):936-44
pubmed: 26667191
Gastroenterology. 2012 Jun;142(7):1592-609
pubmed: 22656328
Life Sci. 2016 Feb 15;147:103-9
pubmed: 26827989
Br J Nutr. 2000 Mar;83(3):257-66
pubmed: 10884714
Dig Dis. 2015;33(4):498-503
pubmed: 26159265
PLoS One. 2016 Aug 10;11(8):e0160639
pubmed: 27509026
Diabet Med. 2006 May;23(5):469-80
pubmed: 16681555
Nat Rev Endocrinol. 2017 Sep;13(9):509-520
pubmed: 28621339
Fed Pract. 2019 Feb;36(2):64-71
pubmed: 30867626
Circulation. 2005 Oct 25;112(17):2735-52
pubmed: 16157765
Phys Med Biol. 2010 Sep 7;55(17):5123-35
pubmed: 20714048
Clin Liver Dis. 2004 Aug;8(3):521-33, viii
pubmed: 15331061
Lancet. 2005 Apr 16-22;365(9468):1415-28
pubmed: 15836891
Endocrinol Metab (Seoul). 2016 Mar;31(1):1-6
pubmed: 26996418
Br J Nutr. 2012 Jun;107 Suppl 2:S8-22
pubmed: 22591906
Nutr Rev. 2004 Jan;62(1):1-17
pubmed: 14995052
Diabetologia. 1985 Jul;28(7):412-9
pubmed: 3899825
J Transl Int Med. 2017 Sep 30;5(3):144-147
pubmed: 29164049
N Engl J Med. 2010 Sep 30;363(14):1341-50
pubmed: 20879883
J Clin Invest. 2011 Jun;121(6):2111-7
pubmed: 21633179
Atherosclerosis. 2020 Mar;296:40-47
pubmed: 32005004
Nutr Metab Cardiovasc Dis. 2021 Jul 22;31(8):2345-2353
pubmed: 34053830
ACS Omega. 2019 Oct 29;4(20):18699-18710
pubmed: 31737831